Levetiracetam
Product Images NDC 53808-1057

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 53808-1057). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 500mg (Levetiracetam 500mg)

Levetiracetam 500 mg tablet label showing quantity of 30 tablets. Labeled by State of Florida DOH Central Pharmacy, Tallahassee, FL. Includes lot number, expiration date, and barcode. RX only.*

FDA Label Image

Label Image For 750mg (Levetiracetam 750mg)

Packaging label for Levetiracetam 750 mg tablets. The label indicates a quantity of 30 tablets, with prescription-only status. Manufacturer is State of Florida DOH Central Pharmacy located in Tallahassee, Florida. The label includes lot number, expiration date, and a barcode.*

FDA Label Image

Figure 1 (Levetiracetam Fig1)

A bar chart showing responder rates (≥50% reduction from baseline) in Study 1 for placebo and two doses of Levetiracetam. The vertical axis represents the percentage of patients, with bars for Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). An asterisk indicates statistically significant differences compared to placebo for both Levetiracetam doses.*

FDA Label Image

Figure 2 (Levetiracetam Fig2)

A bar chart titled 'Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A,' showing the percentage of patients responding to different treatments. The x-axis includes placebo and two dosages of Levetiracetam (1000 mg/day and 2000 mg/day), and the y-axis shows the percentage of patients from 0% to 45%. Response rates are 6.3% for placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day, with a note indicating statistical significance versus placebo.*

FDA Label Image

Figure 3 (Levetiracetam Fig3)

A bar graph titled 'Responder Rate (>50% Reduction From Baseline) In Study 3' comparing the percentage of patients responding to Placebo and Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients, with 14.4% responding to placebo (N=104) and 39.4% responding to Levetiracetam (N=180). A note indicates the Levetiracetam result is statistically significant versus placebo.*

FDA Label Image

Figure 4 (Levetiracetam Fig4)

A bar graph showing the responder rate defined as a 50% or greater reduction from baseline, comparing placebo (19.6% responders) and Levetiracetam (44.6% responders). The graph indicates a statistically significant difference between Levetiracetam and placebo groups.*

FDA Label Image

Figure 5 (Levetiracetam Fig5)

A bar chart titled 'Responder Rate (≥50% Reduction From Baseline) In PGTC Seizure Frequency Per Week' comparing the percentage of patients responding to Placebo and Levetiracetam. The chart shows 45.2% response for Placebo (N=84) and 72.2% for Levetiracetam (N=79), with a note indicating statistical significance versus placebo.*

FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical structure of levetiracetam illustrating its molecular components including a pyrrolidone ring and a side chain with amide and methyl groups, as depicted in the labeled molecular diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.